New treatment for Alzheimer's, prevention of toxic pE-Abeta, QC-Inhibitor to enter Phase II, disease-modifying, dominant IP, no therapy yet
Probiodrug discovers and develops novel drugs for neuronal diseases. Its patent portfolio provides a dominant position for glutaminyl cyclase (QC) inhibition with the lead PQ912 ready to enter Phase II. QC, a novel target, is essential for the formation of pyroglutamated (pE) Abeta, which plays a crucial role in the pathogenesis of Alzheimer’s disease (AD). Likewise, the company is pursuing a pE-specific antibody as immunotherapy for AD.